Marta Sokolowska

And it took place on Monday last week at the agency's White Oak campus, just outside of Washington, D.C., in Maryland.

Here's what FDA's Deputy Center Director for Substance Use and Behavioral Health, Marta Sokolowska, had to say in opening the meeting.

Today's hearing is part of a whole of government effort to better understand the opportunities, challenges, and public health considerations associated with this evolving area of psychedelic drug treatment.

Most importantly, we are here today to listen.